Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Ultragenyx

Tracked across 6 events · 63 articles · First seen Nov 17, 2023 · Last active Sep 23, 2026

Sentiment
2
Attention
4
Events
6
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Regulatory
Impact: Ultragenyx announced that the United States — Food and Drug Administration accepted its resubmitted Biologics License Application for UX111, bringing it closer to potential approval for Sanfilippo syndrome Type A.
Apr 02, 2026 · 6 articles
4 -70
Business
Impact: Ultragenyx is the defendant in a class action lawsuit alleging that it made false and misleading statements regarding its Phase III Orbit and Cosmic Studies for setrusumab, leading to a significant drop in its stock price.
Feb 05, 2026 · 31 articles
0 0
Business
Impact: Ultragenyx granted 65,886 RSUs to 39 new non-executive officers as an inducement, a standard practice to attract talent. The grant is dilutive but immaterial relative to total shares outstanding.
Nov 17, 2023 · 6 articles
4 80
Regulatory
Impact: Developer and manufacturer of Genglycos; the approval is a major commercial milestone, expected to generate revenue and strengthen its gene therapy pipeline.
Aug 20, 2026 · 6 articles
2 -70
Regulatory
Pomerantz LLP announced it is investigating claims on behalf of investors of Ultragenyx regarding potential securities fraud or other unlawful business practices. The investigation follows Ultragenyx's September 2, 2026 press release announcing results from the…
Impact: Ultragenyx is the target of the securities investigation following its failed Phase 3 Aspire study for apazunersen in Angelman syndrome, which caused its stock to plummet 44%. The company faces potential legal liability and reputational damage, with its market value and investor trust significantly impaired.
Sep 08, 2026 · 7 articles
4 0
Business
Impact: Ultragenyx is currently facing a pending lawsuit from the estate of Henrietta Lacks regarding the use of HeLa cells.
Feb 26, 2026 · 7 articles
90 Ultragenyx reported failed Phase 3 studyPomerantz Investigates...
85 Ultragenyx stock fell 44 percentPomerantz Investigates...
70 Pomerantz LLP investigating securities fraud claims UltragenyxPomerantz Investigates...
ERGEN INTELLIGENCE
Track Ultragenyx live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.